MHRA Approves Oral Semaglutide (Wegovy Tablet) for Weight Management in the UKNEW
TL;DR: MHRA approved oral semaglutide (Wegovy tablet) for UK weight management on 11 Jun 2026 — first oral GLP-1 in Europe; OASIS 4 reported 13.6% weight loss.
What Did the MHRA Approve?
On 11 June 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for oral semaglutide 25 mg (brand name Wegovy tablet, manufactured by Novo Nordisk) for chronic weight management in adults. This made the UK the first country in Europe to authorise an oral GLP-1 receptor agonist specifically for weight management.[1]
The indication covers adults with:
- Obesity — body mass index (BMI) of 30 kg/m² or above, or
- Overweight — BMI of 27–29.9 kg/m² — when accompanied by at least one weight-related comorbidity (for example, cardiovascular disease, type 2 diabetes, dyslipidaemia, or hypertension)
The authorisation is as an adjunct to a reduced-calorie diet and increased physical activity in the licensed setting. The oral tablet joins the already-authorised injectable Wegovy 2.4 mg (once-weekly subcutaneous) as a licensed semaglutide-based weight management treatment in the UK.
The US FDA had approved the same formulation earlier, on 22 December 2025, making it the first oral GLP-1 receptor agonist approved for weight management anywhere globally.[2] Novo Nordisk launched the product in the US in January 2026.
What Is Oral Semaglutide and How Does It Differ From the Injection?
Semaglutide is a GLP-1 receptor agonist — a molecule that binds to and activates the glucagon-like peptide-1 receptor. In pharmacological research, activation of the GLP-1 receptor is linked to insulin secretion, gastric emptying, and appetite-regulatory signalling in preclinical models. For a detailed explanation of GLP-1 receptor biology in the context of research peptides, see our guide on what makes a compound a GLP-1 class molecule.
The challenge with delivering any peptide orally is that the gastrointestinal tract is designed to break down protein chains. Most peptides are rapidly degraded by gastric acid and proteolytic enzymes before they can be absorbed. The Wegovy tablet overcomes this through a co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), a small molecule that temporarily raises the local pH around the tablet, reducing proteolytic degradation, and acts as a permeation enhancer to allow semaglutide to cross the gastric epithelium directly — bypassing the small intestine absorption pathway used by most drugs.[3]
The consequence is a distinctly different pharmacokinetic profile compared with the once-weekly subcutaneous injection. Key differences:
| Parameter | Oral semaglutide 25 mg (tablet) | Injectable Wegovy 2.4 mg (s.c.) |
|---|---|---|
| Route | Oral (once daily) | Subcutaneous (once weekly) |
| Absorption mechanism | SNAC-mediated gastric absorption | Subcutaneous depot diffusion |
| Absolute bioavailability | ~0.5–1% (gastric) | ~89% (s.c.) |
| Plasma Cmax profile | Daily peak, lower absolute Cmax | Flat weekly profile, steady state |
| Administration constraint | Empty stomach (8 h fast); wait 30 min before food/drink | Inject at any time, regardless of meals |
| Refrigeration required | No | Yes (before first use) |
| Reported mean weight loss (Phase 3) | 13.6% at 64 weeks (OASIS 4) | ~14.9% at 68 weeks (STEP 1) |
The low absolute bioavailability of the oral formulation is a key research interest point: despite only a fraction of the dose reaching systemic circulation, the clinical trial reported a comparable weight-management outcome to the injectable, suggesting that the threshold receptor occupancy required for the observed effects is achievable even at these plasma concentrations. This has implications for GLP-1 receptor research models examining dose–response relationships.
What Did the OASIS 4 Phase 3 Trial Report?
Everything in this section describes what a published human clinical trial reported. It is a summary of third-party research findings, cited for scientific reference. It is not a description of any effect of Velox Peptides products, and nothing here should be read as guidance.
The OASIS 4 trial enrolled 307 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) plus at least one weight-related comorbidity, without type 2 diabetes. Participants were randomised to once-daily oral semaglutide 25 mg or placebo for 64 weeks, with all participants receiving dietary guidance and physical activity counselling.
At the 64-week primary endpoint, the trial reported:
- Mean body-weight reduction: 13.6% (semaglutide) vs 2.2% (placebo)
- Treatment-adherence estimand: 16.6% vs 2.7% placebo
- 76% of semaglutide participants achieved ≥5% body-weight reduction, versus 31% on placebo
- 51% of semaglutide participants achieved ≥10% body-weight reduction
- 29% of semaglutide participants achieved ≥15% body-weight reduction
The tolerability profile was consistent with the GLP-1 class: gastrointestinal adverse events (nausea, vomiting, diarrhoea) were the most common, predominantly during the dose-escalation phase. Discontinuation rates due to adverse events were higher in the semaglutide arm than placebo.
The OASIS 4 data were submitted to both the FDA (NDA accepted December 2025) and MHRA (marketing authorisation June 2026) as part of the regulatory filings. The FDA approval in December 2025 also noted a reduction in risk of major adverse cardiovascular events (MACE), consistent with the SELECT trial data from injectable semaglutide.[2]
The Oral Semaglutide Regulatory Timeline
Who Can Access Oral Semaglutide in the UK, and When?
As of the date of this article (22 June 2026), oral semaglutide (Wegovy tablet) has MHRA marketing authorisation in the UK, but is not yet available on the NHS. It can be prescribed privately by a registered UK prescriber to eligible adults meeting the MHRA's licensed indications. Novo Nordisk has indicated that private supply through specialist clinics is expected within weeks of the June 2026 approval.[1]
NHS access requires a separate evaluation by the National Institute for Health and Care Excellence (NICE). Given that NICE has already approved injectable semaglutide (Wegovy injection) for specific NHS pathways, an evaluation of the oral formulation was expected to begin following MHRA authorisation. No completion date was confirmed at time of publication.
It is worth noting that the oral formulation's administration requirements are significantly stricter than the injection: it must be taken fasted (at least 8 hours without food or drink other than a small sip of water), and no food or drink should be consumed for at least 30 minutes after taking the tablet. This pharmacokinetic constraint — arising from the SNAC absorption mechanism — is a practical consideration for licensed clinical use, and also makes it an interesting research model for studying GLP-1 receptor activation under controlled temporal conditions.
How Does This Fit the GLP-1 Research Landscape in 2026?
The MHRA approval of oral semaglutide is a significant point on a trajectory that began with GLP-1 receptor agonist research in the 1990s. The landscape in June 2026 now includes three generations of licensed GLP-1-class medicines, a pipeline of more complex multi-receptor compounds, and — for laboratory researchers — a growing body of published mechanistic data to work from.
For researchers tracking the incretin and GLP-1 receptor field, the oral vs injectable distinction is particularly notable because it creates two discrete pharmacokinetic patterns acting at the same receptor. The SNAC-mediated oral absorption produces daily fluctuating plasma levels, while once-weekly injection produces a flatter, sustained exposure profile. Whether these different temporal exposure patterns produce identical receptor occupancy and downstream signalling in in vitro and animal models is an open question that this regulatory milestone may stimulate further investigation into.[3]
The three licensed-medicine generations as of June 2026:
| Generation | Example compound (licensed) | Receptor targets | Route | Phase 3 weight loss (mean) |
|---|---|---|---|---|
| First (single agonist, injectable) | Semaglutide (Wegovy inj.) | GLP-1 | s.c. weekly | ~14.9% (STEP 1, 68 wk) |
| First (single agonist, oral) | Oral semaglutide (Wegovy tab.) | GLP-1 | Oral daily | 13.6% (OASIS 4, 64 wk) |
| Second (dual agonist) | Tirzepatide (Zepbound/Mounjaro) | GLP-1 + GIP | s.c. weekly | ~22.5% (SURMOUNT-1, 72 wk) |
| Third (triple agonist, in trials) | Retatrutide (LY3437943) | GLP-1 + GIP + Glucagon | s.c. weekly | 28.3% (TRIUMPH-1, 80 wk) |
Retatrutide (LY3437943) — the only triple receptor agonist to have reached Phase 3 — has reported 28.3% mean body-weight reduction in the TRIUMPH-1 trial and is not yet licensed. Eli Lilly has indicated an NDA submission to the FDA is targeted for Q4 2026. For detailed analysis of the TRIUMPH-1 data, see our TRIUMPH-1 Phase 3 guide. For a comparison of retatrutide against injectable semaglutide specifically, see Retatrutide vs Wegovy.
For researchers working with GLP-1-class peptides in vitro, the regulatory approval of an oral formulation highlights the increasing research interest in GLP-1 receptor activation across different dosing paradigms. Velox Peptides supplies GLP-1-class research compounds, including retatrutide for in vitro research, through our metabolic research compounds catalogue.
Frequently Asked Questions
What did the MHRA approve on 11 June 2026?
On 11 June 2026 the MHRA approved oral semaglutide 25 mg (Wegovy tablet, made by Novo Nordisk) as a once-daily tablet for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI 27–29.9) with at least one weight-related comorbidity. This was the first oral GLP-1 receptor agonist approved for weight management in Europe.
What did the OASIS 4 trial report for oral semaglutide?
OASIS 4 was a Phase 3 RCT (n=307, 64 weeks). It reported 13.6% mean body-weight reduction for oral semaglutide 25 mg versus 2.2% for placebo. Under the treatment-adherence estimand the figure was 16.6%. 76% of participants on semaglutide achieved ≥5% weight loss versus 31% on placebo. These are third-party trial findings reported for scientific reference only.
Is oral semaglutide available on the NHS?
As of June 2026, oral semaglutide has MHRA marketing authorisation but is not yet NHS-reimbursed. A NICE technology appraisal is required before NHS availability. Private prescriptions may be available through specialist weight management services.
How does the oral tablet differ from the Wegovy injection?
The tablet uses SNAC to enable gastric absorption of the peptide, producing a daily oral dose with lower absolute bioavailability (~0.5–1%) but a clinically similar weight-management outcome to once-weekly injection. It must be taken fasted on an empty stomach with a small sip of water, with food and drink avoided for 30 minutes post-dose. The injection has ~89% bioavailability and no food restriction at the time of administration.
How does oral semaglutide compare to retatrutide in research data?
These compounds target different receptor profiles and are at different regulatory stages. Oral semaglutide is a licensed medicine (single GLP-1 agonist) reporting 13.6% mean weight loss in 64 weeks (OASIS 4). Retatrutide is a triple GLP-1/GIP/glucagon agonist still in Phase 3 trials, reporting 28.3% mean weight loss at 80 weeks (TRIUMPH-1, 12 mg dose). The trials used different populations, durations and designs; cross-trial comparison is methodologically limited. For a detailed breakdown, see our Retatrutide vs Wegovy guide.
What is SNAC and why does it matter for GLP-1 peptide research?
SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) is a permeation enhancer that temporarily buffers the gastric microenvironment around the semaglutide tablet, reducing peptide proteolysis and facilitating absorption across the gastric epithelium. It allows a large peptide (molecular weight ~4,113 Da) to achieve meaningful oral bioavailability — a longstanding challenge in peptide drug delivery. For researchers studying oral peptide delivery or GLP-1 receptor activation kinetics, the SNAC mechanism represents a distinct experimental paradigm compared with parenteral administration.
References
- MHRA. "First GLP-1 tablet for weight loss approved in the UK." GOV.UK press release, 11 June 2026. gov.uk
- Novo Nordisk. "Wegovy pill FDA approval." Company announcement, 22 December 2025. novonordisk.com
- Buckley ST et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." Sci Transl Med. 2018;10(467):eaar7047. PMID: 30429357
- OASIS 4 Investigators. "Oral semaglutide at a dose of 25 mg in adults with overweight or obesity." New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2500969
- Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384(11):989–1002 [STEP 1]. PMID: 33567185
- Jastreboff AM et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(3):205–216 [SURMOUNT-1]. PMID: 35658024